Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Feb 22, 2020 11:34am
88 Views
Post# 30721042

RE:RE:RE:RE:BREAKING NEWS

RE:RE:RE:RE:BREAKING NEWS
Ingiboy wrote: Metzger stop ranting about Shiseido. You keep saying Replicel is not meeting/talking to Shiseido. On that point you are completely wrong. I don't know the details but I do know Replicel has retained laywers to pursue a breach of contract.  Unfortunately these things take time.  I too as I have stated numerous times are frustrated in how long this is taking.  I thought by now we would have gotten some idea as to what is happening but rest assured something is definetely in the works.  
I think Replicel would like to update the market as to where this is at but I assume the lawyers have told them not to until the dispute is settled.  Let's hope it is soon and in Replicel's favour.


How do you know Replicel have retained lawyers? Was there an email/update? I missed if there was...can you link it for me please. Thanks
Bullboard Posts